
TrumpRx’s promised drug-price cuts expose a deeper systemic flaw, positioning direct-to-patient clinical pathways as the infrastructure pharma must build to turn political headlines into real access and outcomes.

Co-founder and CEO, ixlayer

Published: January 16th 2025 | Updated: